Recent Reports

Evidence report on anti-androgen drugs for high risk prostate cancer. This report will serve as the basis for discussion during a public meeting of Midwest CEPAC in September 2018.

View More on this Topic

ICER’s Draft Evidence Report, open to public comment until September 20, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

Pharmaceutical Rebates: Journal Publication

ICER

Model Transparency: Journal Publication

ICER

Atopic Dermatitis: Journal Publication

Sharable Cost-Effectiveness Models: Journal Publication

Abuse-Deterrent Opioids: Journal Publication

Evaluating Rare Conditions: Journal Publications

Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: Journal Publication

Current Value Frameworks: Journal Publication

Inherited Retinal Disease: Journal Publication

ICER’s Value Framework and Patient Feedback: Q&A with Steve Pearson

CTAF

Ulcerative Colitis: Stakeholder List

CTAF

Ulcerative Colitis: Draft Scoping Document